IMV Стоимость предприятия

Что обозначает Стоимость предприятия в IMV?

Стоимость предприятия IMV, Inc. является $25.88M

Какое определение для Стоимость предприятия?



Стоимость предприятия является измерением общей рыночной стоимости компании. Она рассчитывается как рыночная капитализация с учётом долга, доли меньшинства и привилегированных акций за вычетом общей суммы денежных средств и их эквивалентов.

It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.

Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.

Стоимость предприятия компаний в Health Care сектор на TSX по сравнению с IMV

Что делает IMV?

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Компании с стоимость предприятия похож на IMV



  • Volatus Aerospace Corp имеет Стоимость предприятия из $25.84M
  • Technologies имеет Стоимость предприятия из $25.84M
  • Bigblu Broadband plc имеет Стоимость предприятия из $25.85M
  • Fremont Petroleum имеет Стоимость предприятия из $25.87M
  • HighGold Mining имеет Стоимость предприятия из $25.87M
  • Asia Commercial имеет Стоимость предприятия из $25.87M
  • IMV имеет Стоимость предприятия из $25.88M
  • Bionomics имеет Стоимость предприятия из $25.89M
  • DMG Blockchain Solutions имеет Стоимость предприятия из $25.89M
  • Mallinckrodt plc имеет Стоимость предприятия из $25.90M
  • Alien Metals имеет Стоимость предприятия из $25.91M
  • Vst Building Techs Ag имеет Стоимость предприятия из $25.92M
  • Invitrocue имеет Стоимость предприятия из $25.93M